Epitherapeutics has announced the participation of OSI Pharmaceuticals Inc. in an extension of its seed round, bringing the total seed financing to DKK 42 M since the inception of Epitherapeutics in October 2008. OSI Pharmaceuticals Inc. joins an investor group that includes LFI Life Science Investments, Novo Seeds and Seed Capital.
The new financing will support the further drug discovery efforts at Epitherapeutics and will fuel the work on building a pipeline of novel small-molecule inhibitors against selected epigenetic oncology targets. The discovery of such inhibitors is done in close collaboration with Prof. Kristian Helin’s laboratory at BRIC, University of Copenhagen. Prof. Helin, a co-founder of Epitherapeutics, is a world leader in the field of basic oncology research and involved in the discovery and validation of various epigenetic enzymes. Epigenetic enzymes are believed to play a key role in numerous human diseases, including oncology.